Literature DB >> 7929757

Comparison of commercial kits for detection of cryptococcal antigen.

D C Tanner1, M P Weinstein, B Fedorciw, K L Joho, J J Thorpe, L Reller.   

Abstract

Although kits to detect cryptococcal antigen are used widely to diagnose cryptococcal infection, the comparative performance of commercially available assays has not been evaluated in the past decade. Therefore, we compared the sensitives and specificities of five commercially available kits for detecting cryptococcal antigen (four latex agglutination test kits--Calas [Meridian Diagnostics])--Crypto-LA [International Biological Labs], Myco-Immune [MicroScan], and Immy [Immunomycologics]--and an enzyme immunoassay kit, Premier [Meridian Diagnostics]) with culture for the diagnosis of cryptococcal meningitis and fungemia. Of 182 cerebrospinal fluid (CSF) and 90 serum samples submitted for cryptococcal antigen and fungal culture, 49 (19 and 30 samples, respectively) from 20 patients had a culture positive for Cryptococcus neoformans. For CSF specimens, the sensitivities and specificities of all kits were comparable (sensitivity, 93 to 100%; specificity, 93 to 98%). There was a significant difference in sensitivities of the kits when serum samples were tested with the International Biological Labs and MicroScan kits, which do not pretreat serum with pronase. These kits were less sensitive (sensitivity, 83%) than the Immy and Meridian latex kits (sensitivity, 97%), which do pretreat with pronase. The sensitivity of the Meridian enzyme immunoassay kit was comparable to that of the pronase-containing latex kits. These kits were of equivalent specificities (93 to 100%) when testing serum. Some of the currently available kits have limitations that need to be recognized for proper interpretation of results. Specifically, the use of pronase on serum samples reduces the number of false-positive results, and a titer of < or = 1:4 can be a false-positive result when CSF samples are being tested.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929757      PMCID: PMC263761          DOI: 10.1128/jcm.32.7.1680-1684.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus.

Authors:  R A Clark; D Greer; W Atkinson; G T Valainis; N Hyslop
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

2.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

3.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.

Authors:  R A Larsen; M A Leal; L S Chan
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

4.  Experience with the use of pronase to eliminate interference factors in the latex agglutination test for cryptococcal antigen.

Authors:  L D Gray; G D Roberts
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

5.  Cryptococcal infections in patients with acquired immune deficiency syndrome.

Authors:  R H Eng; E Bishburg; S M Smith; R Kapila
Journal:  Am J Med       Date:  1986-07       Impact factor: 4.965

6.  Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome.

Authors:  S L Chuck; M A Sande
Journal:  N Engl J Med       Date:  1989-09-21       Impact factor: 91.245

7.  Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment.

Authors:  J R Hamilton; A Noble; D W Denning; D A Stevens
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

8.  Itraconazole therapy for cryptococcal meningitis and cryptococcosis.

Authors:  D W Denning; R M Tucker; L H Hanson; J R Hamilton; D A Stevens
Journal:  Arch Intern Med       Date:  1989-10

9.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

Authors:  A Zuger; E Louie; R S Holzman; M S Simberkoff; J J Rahal
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

10.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; R A Larsen; J Chiu; M A Leal; J Jacobsen; P Rothman; P Robinson; G Gilbert; J A McCutchan; J Tilles
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

View more
  42 in total

1.  Cryptococcal eosinophilic meningitis in a patient with sarcoidosis.

Authors:  Hiba Hadid; Paul Nona; Muhammad Usman; David Paje
Journal:  BMJ Case Rep       Date:  2015-12-18

2.  Development of a nested PCR for detection of Cryptococcus neoformans in cerebrospinal fluid.

Authors:  P Rappelli; R Are; G Casu; P L Fiori; P Cappuccinelli; A Aceti
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

3.  Comparison of four assays for the detection of cryptococcal antigen.

Authors:  M J Binnicker; D J Jespersen; J E Bestrom; L O Rollins
Journal:  Clin Vaccine Immunol       Date:  2012-10-17

4.  Delayed diagnosis of cryptococcal meningoencephalitis due to negative cryptococcal antigen test.

Authors:  Bernhard Kessler; Frank Bally; Ekkehard Hewer; Parham Sendi
Journal:  BMJ Case Rep       Date:  2013-01-29

5.  Cerebrospinal T-cell responses aid in the diagnosis of tuberculous meningitis in a human immunodeficiency virus- and tuberculosis-endemic population.

Authors:  Vinod B Patel; Ravesh Singh; Cathy Connolly; Yacoob Coovadia; Abdool K C Peer; Priyashini Parag; Victoria Kasprowicz; Alimuddin Zumla; Thumbi Ndung'u; Keertan Dheda
Journal:  Am J Respir Crit Care Med       Date:  2010-05-04       Impact factor: 21.405

6.  False-positive cerebrospinal fluid cryptococcus antigen in Libman-Sacks endocarditis.

Authors:  Iyad N Isseh; Kassem Bourgi; Asaad Nakhle; Mahmoud Ali; Marcus J Zervos
Journal:  Infection       Date:  2016-05-31       Impact factor: 3.553

7.  Enzyme immunoassay versus latex agglutination cryptococcal antigen assays in adults with non-HIV-related cryptococcosis.

Authors:  Anil A Panackal; John P Dekker; Michael Proschan; Andrea Beri; Peter R Williamson
Journal:  J Clin Microbiol       Date:  2014-09-24       Impact factor: 5.948

8.  Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis.

Authors:  Joseph N Jarvis; Ann Percival; Sean Bauman; Joy Pelfrey; Graeme Meintjes; G Ntombomzi Williams; Nicky Longley; Thomas S Harrison; Thomas R Kozel
Journal:  Clin Infect Dis       Date:  2011-09-21       Impact factor: 9.079

9.  PCR detection of DNA specific for Trichosporon species in serum of patients with disseminated trichosporonosis.

Authors:  H Nagai; Y Yamakami; A Hashimoto; I Tokimatsu; M Nasu
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 10.  Opportunistic Neurologic Infections in Patients with Acquired Immunodeficiency Syndrome (AIDS).

Authors:  Fritzie Albarillo; Paul O'Keefe
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.